The Supreme Court changes biotech deal flow

Abstract

In the recent case of Integra LifeSciences vs. Merck KGaA, the US Supreme Court has provided a broad exemption to patent infringement that could change the way that deals are done in the biotech arena. Companies can now develop new drugs free from patent infringement. How do you now negotiate deals in light of this decision?

Keywords::

• generic drug
• research tool
• safe harbour
• stem cell